Mirador Capital Partners LP Increases Position in Johnson & Johnson (NYSE:JNJ)

Mirador Capital Partners LP lifted its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,659 shares of the company’s stock after purchasing an additional 281 shares during the period. Mirador Capital Partners LP’s holdings in Johnson & Johnson were worth $1,706,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Veracity Capital LLC increased its stake in shares of Johnson & Johnson by 1.2% during the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after purchasing an additional 59 shares in the last quarter. Sandy Cove Advisors LLC increased its stake in shares of Johnson & Johnson by 1.6% during the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock worth $605,000 after purchasing an additional 60 shares in the last quarter. LCM Capital Management Inc increased its stake in shares of Johnson & Johnson by 0.7% during the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock worth $1,667,000 after purchasing an additional 61 shares in the last quarter. Arbor Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 2.3% during the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock worth $476,000 after purchasing an additional 61 shares in the last quarter. Finally, Sierra Capital LLC increased its stake in shares of Johnson & Johnson by 0.6% during the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock worth $1,773,000 after purchasing an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Activity

In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a report on Wednesday, April 19th. UBS Group started coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target on the stock. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. Finally, Atlantic Securities decreased their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $158.91 on Monday. The company has a market capitalization of $412.96 billion, a price-to-earnings ratio of 33.24, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The firm’s fifty day moving average price is $159.70 and its 200 day moving average price is $166.20. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. During the same quarter in the prior year, the business earned $2.67 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.6% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. The ex-dividend date of this dividend is Monday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio (DPR) is 94.56%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.